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Abstract

Globally, R&D is recognized as an important driver of economic and social progress. In 2013,
the Dominican Republic invested only 0.3% of GDP (Gross Domestic Product) in R&D
expenditure, which is a level of investment equivalent to half the Latin American average. The
globalization process has allowed many corporations to internationalize their value chain
including R&D activities, which represents an extraordinary opportunity for a developing
country as the Dominican Republic to attract FDI (Foreign Direct Investment) as a way to
increase innovation process related to R&D activities. This research project investigates whether
R&D expenses have an effect on the profit, revenue, and productivity for companies of high-tech
healthcare products in the Dominican Republic, and why some of these companies do not invest
more in R&D inside the country. The research adopted a mixed methods approach by using
quantitative research (survey and content analysis) and qualitative research (interviews). The
results suggest that companies surveyed concentrate their main R&D programs outside the
country due to lack in quality and the capacity through government or academic institutes to
engage in complex R&D activities required by these firms. As a result, the companies surveyed
only perform process innovation and product testing in their manufacturing facilities. Also,
cooperation among (company-university-government) in the innovation system has become
ineffective. In this sense, it is necessary a strong effort from all stakeholders involved in
innovation policy to lift the quality and magnitude of R&D spending in the Dominican Republic,
as a way to increase nation’s competitiveness and innovation.
Keywords: R&D, innovation, competitiveness, productivity, globalization
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Chapter 1: Introduction
1.1. Background
Economic globalization and advances in technology have significantly increased market
competitiveness. Consequently, innovation, R&D, and education are three extraordinary
opportunities for the Dominican Republic that need to be interconnected as a necessity to
develop the human capital required for building the society of the future.
Nowadays, the Dominican Republic invests only 0.3% of GDP (Gross Domestic Product)
in Research and Development expenditure, which is a level of investment equivalent to half the
Latin American average and is far below that of most developed countries (Legatum Institute,
2013). In this context, investing more in R&D is a way to improve innovation, in order to
increase the competitiveness of the Dominican Republic in the global market. Innovation has to
be actively encouraged and supported by the government, universities and stakeholders.
Today, the Dominican Republic is a hub for top medical technology companies which
have chosen the country for developing and manufacturing a wide range of sophisticated medical
products, creating one of the largest clusters in healthcare manufacturing in the region. In this
context, the medical device industry in the Dominican Republic has played a key role in
promoting and sustaining economic growth of the country, due to a significant and sophisticated
network of experienced people and companies, whom are incorporating new and advanced
technologies.
This study will (1) improve our understanding of R&D effects on manufacturing
companies of high-tech healthcare products in the Dominican Republic; (2) provide a better
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understanding of innovation process and economic growth to improve the overall
competitiveness of the Dominican Republic in the global market; (3) create the strategies to
develop the effective methods to promote more intensively R&D investment in different
industries of the Dominican Republic.
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1.2. Problem Statement
Nowadays, the Dominican Republic invests only 0.3% of GDP (Gross Domestic Product)
in Research and Development expenditure, which is a level of investment equivalent to half the
Latin American average and is far below that of most developed countries (Legatum Institute,
2013). In this context, investing more in R&D is a way to improve innovation and economic
growth, in order to increase the competitiveness of the Dominican Republic in the global market.
Investing in R&D has great potential for benefiting broader society. This research project
investigates whether R&D expenses have an effect on the profit, revenue, and productivity for
companies of high-tech healthcare products in the Dominican Republic, and why some of these
companies do not invest more in R&D.

1.3 The Central Research Questions

1. What % of budget is invested in R&D by manufacturing companies of high-tech
healthcare products in the Dominican Republic?

2. What are the barriers to investing resources in R&D in the high tech manufacturers in
the Dominican Republic?
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1.4 Significance Statement
R&D is recognized as an important driver of economic and social progress worldwide. It
can be a powerful source to improve productivity, innovation, and competitiveness; to help to
reduce poverty, and to stimulate long-term economic growth. The OECD (Organization for
Economic Cooperation and Development) emphasizes the hazards of cutting spending on R&D
and other investments that support innovation and economic growth, declaring, cutting back
public investment in support of innovation may provide short-term fiscal relief, but will damage
the foundations of long terms growth (OECD, 2010). In 2005, industryweek.com did a study
about the effects of innovation based on R&D expenses and they found that, “overall revenue
growth (78%), increased productivity (71%), and profits margins (68%)” were a result of the
impact of R&D efforts. This research project will guide us to develop a more accurate
understanding of the real impact that R&D expenses can make on manufacturing companies in
the Dominican Republic. By providing a systematic, detailed understanding of the innovation
process, this study will (1) improve our understanding of R&D effects on manufacturing
companies of high-tech healthcare products in the Dominican Republic; (2) provide a better
understanding of innovation process and economic growth to improve the overall
competitiveness of the Dominican Republic in the global market; (3) create the strategies to
develop the effective methods to promote more intensively R&D investment in different
industries of the Dominican Republic.
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1.5 Hypotheses



Companies of high-tech healthcare products in the Dominican Republic, which invest
more in R&D, are more profitable than those who invest less.



Companies of high-tech healthcare products in the Dominican Republic, which invest
more in R&D increases their revenue than those who invest less.



Companies of high-tech healthcare products in the Dominican Republic, which invest
more in R&D increases their productivity levels than those who invest less.
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Chapter 2: Literature Review
2.1 Literature Review
Today, as new technologies are arriving to the market faster than ever before and the
world is becoming more connected. There is a necessity to develop the right tools and solutions
to deliver the best value to the customers. In any sector of the economy, this necessity is driven
by innovation in process, products and services with the objective to enhance the experience and
value to the customer. Also, economic globalization and advances in technology have
significantly increased market competitiveness. Consequently, innovation, R&D, and education
are three extraordinary opportunities for the Dominican Republic that need to be interconnected
as a necessity to develop the human capital required for building the society of the future.
In this context, several studies indicate that investment in R&D will foster the capacity to
create, spread, adopt, and adapt knowledge in ensuring long-term economic growth and
sustainable development. A higher productivity level based on innovation promotes economic
growth, creates employment with better levels of remuneration, reduces poverty on a sustainable
basis and raises general living standards. The creation and spread of knowledge is carried out by
government, businesses, universities, research institutes, and nonprofit organizations.
R&D is recognized as an important driver of economic and social progress worldwide. It
can be a powerful source to improve productivity, innovation, and competitiveness; to help to
reduce poverty, and to stimulate long-term economic growth. The OECD (Organization for
Economic Cooperation and Development) emphasizes the hazards of cutting spending on R&D
and other investments that support innovation and economic growth, declaring, cutting back
public investment in support of innovation may provide short-term fiscal relief, but will damage
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the foundations of long terms growth (OECD, 2010). In 2005, industryweek.com did a study
about the effects of innovation based on R&D expenses and they found that, “overall revenue
growth (78%), increased productivity (71%), and profits margins (68%)” were a result of the
impact of R&D efforts.
Nowadays, the Dominican Republic invests only 0.3% of GDP (Gross Domestic Product)
in Research and Development expenditure, which is a level of investment equivalent to half the
Latin American average and is far below that of most developed countries (Legatum Institute,
2013). In this context, investing more in R&D is a way to improve innovation, in order to
increase the competitiveness of the Dominican Republic in the global market. Innovation has to
be actively encouraged and supported by the government, universities and stakeholders.
Developing countries, such as Kenya, Senegal, Tanzania, and Uganda are currently
investing between 0.5% and 1% of their gross domestic product in Research and Development
(World Bank, 2013).
Innovative value-added products and services have direct effects on competitive
advantages. For example, in Latin America some countries that export more complex products
enjoy more prosperity that those only export commodities or those that are based on comparative
advantages alone. These are the cases of Chile, Brazil, Costa Rica, and Mexico, in which they
export high-end products and services. For example, large global companies based in Brazil
include oil and gas producer Petrobras, mining company Vale, aircraft manufacturer Embraer
who designed and manufactured aircrafts completely in the country; Mexican multinationals
include Bimbo, the world’s largest bread manufacturer; building materials manufacturer
CEMEX; and telecom giant America Movil.
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The global markets generate pressure for companies to innovate and improve, in order to
create new and better products, processes or services. For that reason, the innovation dynamics
are relevant to create the business environment to pursue better competitive advantage for the
country. At present, R&D expenditure is considered as an asset for the government and all
stakeholders. Also, the government and companies will be able to utilize some of the results of
its R&D to be transferred through various channels, such as: licensing and cooperation between
companies. Knowledge generated as a result of R&D is not a public good that can be utilized by
just anyone (Callon, 1994). In this case, a certain form of education and the right networks are
required to be able to understand and utilize new knowledge from R&D. In this context, the
social return on the R&D performed by companies is greater than the private return. For
example, the private return is on average 20% to 35%, while the social return may be two to
three times higher. According to the (Global Competitiveness Index, 2015) provided by the
World Economic Forum, the Dominican Republic ranks on places 73th and 105th in business
sophistication and innovation respectively from 144 countries evaluated (see Figure 2.1).
Innovation and R&D are important for the economy. They can be mutually reinforcing and
together can be a powerful source of improved productivity and competitiveness, helping to
reduce poverty and stimulate long-term economic growth (World Bank, 2013). Investments in
R&D that provide new knowledge are seen as an important factor that explains growth and
increased productivity (Romer, 1990).
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Figure 2.1 The Global Competitiveness Index 2015 - Illustrates the Overall Performances of the
Dominican Republic in the Global Market.

Note. From World Economic Forum. (2014). The Global Competitiveness Report 2014-2015.
Retrieved from World Economic Forum: www.weforum.org/issues/global-competitiveness

According to the last data of the Observatory of Economic Complexity developed by the
Massachusetts Institute of Technology (MIT), exports in 2012 for the Medical Instruments in the
Dominican Republic was a 15.37% of the free zone exports or US$952 Million (see Figure 2.2)
and 1.06% of the global commerce of Medical Instrument. This represents a consolidated
position of medical devices in the export sector. Investment in R&D is a determining factor for
the successful acquisition of foreign technology. However, in the Dominican Republic, a lack of
R&D investment limits the capacity to develop the strategies and the tools required at promoting
innovation. International organizations, such as: the IMF, World Bank, OECD, and the World
Economic Forum suggest that developing countries should invest very heavily in R&D.
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The estimates of the return to R&D expenditure for advanced countries have been so high
to justify intensive levels of investment (Jones and Williams, 1998). Also, investigators argue
that R&D in developing countries is essential to support the absorptive process of technological
advance developed in other countries.
Figure 2.2 Countries that Export Medical Instruments (2012) - Illustrates the Overall
Performances of the Dominican Republic in Medical Instruments exports.

Note. From MIT-Observatory of Economic Complexity. (2012). Countries that export Medical
Instruments (2012). Retrieved 2014, from MIT:
http://atlas.media.mit.edu/en/explore/tree_map/hs/export/show/all/9018/2012/
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According to the UNCTAD-United Nations Conference on Trade and Development(2010) in the investigation "Science, Technology & Innovation Policy Review: Dominican
Republic" developed two survey to measure innovation activities in two sectors: the business
sector and the academic and scientific sector, such as institutions of higher education and
research centers.

The results of that survey show that there are a significant number of

companies that innovate in products (55%) and processes (73%), and that those innovations are
usually of an imitative nature, incremental and not radical. Also, more than 80% of the
companies that innovate in processes or products declared that the innovations introduced were
new for that company but not for its geographical market.
The survey also shows that companies rarely cooperate with other institutions or
companies in innovating (see Figures 2.3, 2.4, 2.5). There is a notable absence of cooperation
with universities. In this context, an identifiable characteristic of innovative companies in the
Dominican Republic is the significant influence that the level of managers’ training has on the
intensity of the innovative activity. In general, the results based on the responses indicate a low
level of private R&D investment in all economic sectors. Other characteristic is that financing
for innovation usually comes from the business itself (more than 88% of the companies used
their own resources). In perspective, the role of venture capital companies and the direct support
of government entities to finance innovation are very limited in the Dominican Republic.

MEASURING AND PROMOTING R&D IN THE DOMINICAN REPUBLIC

12

Figure 2.3 Innovations in Processes in the Dominican Republic, 2003-2009.

Note. UNCTAD. (2012). Science, technology & innovation policy review: Dominican Republic. Retrieved
from http://unctad.org/en/publicationslibrary/dtlstict2012d1_en.pdf

Figure 2.4 The Novelty of Innovation Activities, Dominican Republic, 2003-2009.

Note. UNCTAD. (2012). Science, technology & innovation policy review: Dominican Republic.
Retrieved from http://unctad.org/en/publicationslibrary/dtlstict2012d1_en.pdf
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Figure 2.5 Sources of Financing for the Innovation, Dominican Republic, 2003-2009.

Note. UNCTAD. (2012). Science, technology & innovation policy review: Dominican Republic. Retrieved
from http://unctad.org/en/publicationslibrary/dtlstict2012d1_en.pdf

Today, the Dominican Republic is a hub for top medical technology companies which
have chosen the country for developing and manufacturing a wide range of sophisticated medical
products, creating one of the largest clusters in healthcare manufacturing in the region. In this
context, the medical device industry in the Dominican Republic has played a key role in
promoting and sustaining economic growth of the country, due to a significant and sophisticated
network of experienced people and companies, whom are incorporating new and advanced
technologies.
However, overall investment in R&D activities in health sector was estimated to be
0.06% of the GDP according to a survey made by Bravo (Bravo et al, 2004). In this study, it was
estimated that in the Dominican Republic there were with 359 researchers (72.7% with a
Master’s degree and 29.5% with a Ph.D.) in 2004, but only 57.6 % of those work full time on
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research. According to the same source, it was estimated that 24% of the researchers work in the
field of health, which means 86 researchers. In fact, this is a very small number given the
country’s size and the challenges it faces in the field of health. At present, 150 companies
operate in the health sector, of which 39 are Dominican. According to CEI-RD (Center for
Export and Investment of the Dominican Republic), the pharmaceutical industry supports
approximately 10,000 jobs, which represents 3% of total industrial employment and 0.3% of the
economically active population.
There is no solid evidence that health industry carries out significant research activities
in the country. In this context, the report of Mullin Consulting (2003) makes reference that the
Dominican innovation system is built around the diffusion and absorption of external knowledge,
where equipment suppliers play a key role. As a result, the few companies that are capable of
creating and managing technical innovation will continue to be more the exception than the rule.
Also, the innovation survey developed by Grupo Consultoría Pareto (2007) confirms the
perception that the industry vision is disconnected from the universities and centers of research,
as illustrated in Figure 2.6. According to the chart 2.6, 90.5% of source of innovation is provided
by the company itself, and the work with universities is only 0.7%.
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Figure 2.6 Sources of Innovations Made by Innovative Dominican Companies.

Note. UNCTAD. (2012). Science, technology & innovation policy review: Dominican Republic. Retrieved
from http://unctad.org/en/publicationslibrary/dtlstict2012d1_en.pdf

This chart (Figure 2.6) reveals that cooperation between the elements of the innovation
system is ineffective. For that reason, economic incentives in R&D must be established for
projects that link the industry and academic institutions. However, the key to support an effective
R&D program between companies and universities should consider aspects, such as: intellectual
property, diagnostic of companies’ technological needs, financial instruments, and standard
operating procedures.
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In this context, Wieser (2005) suggests that R&D has a positive and statistically
significant effect on growth in terms of sales and productivity. In his study, the private return for
investing in R&D is between 7% and 69%. The median is 27% and the mean value is 28%. Also,
the return to other companies is considered twice as high as the private return, which means that
the social return (private return + spillovers) is on average 90% to 100%. Consequently, the
social return on R&D is very important in an economic-political perspective, this one of the
reason that motivates the government to fund R&D. Some empirical studies suggest that publicfunding in the form of direct funding or tax incentives stimulates rather than replaces private
R&D. However, in the case of the transfer of technology from the universities to industry, it is
necessary to develop the best strategies and policies that allow the universities and all researchers
involved in the R&D process, to pursue a future commercialization of their inventions or
innovations.
As we have seen, the literature review suggests that for developing countries is necessary
a strong effort to lift the quality and magnitude of R&D spending, as a way to increase economic
growth, innovation, and entrepreneurship. The extraordinary growth in R&D performed by the
BRIC (Brazil, Russia, India and China) countries in the last decade, may be justified by the fact
of compromise between the government and all stakeholders that support R&D process, for
improving the quality of human capital, strengthening research institutions, implementing a
national innovation system, and raising the sophistication of the private sector to compete
globally. In perspective, R&D is recognized as an important driver of economic and social
progress worldwide. It can be a powerful source to improve productivity, innovation, and
competitiveness; to help to reduce poverty, and to stimulate long-term economic growth.
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2.2 Statistical Overview of the Population of this Study
The free zone regime (Act 8-90) in the Dominican Republic has become the central
platform for growth and development of manufacturing Medical and Pharmaceutical products.
According to data recorded by the National Council of Free Zones (CNZF), in 2013, a total of
twenty six companies in the medical and pharmaceutical industry were operating under the free
zone regime, generating about 17,000 direct jobs and more US$1,230 million in foreign
exchange.
The development of the sector of medical and pharmaceutical products, also known as
"The Life Sciences Industry" in the free zones of the Dominican Republic was originated in the
late eighties. However, the installation of the medical industry companies would not have been
possible without the existence of an appropriate industrial infrastructure in the Dominican
Republic, which could be successfully provided by the Parks Zone located on the outskirts of the
city of Santo Domingo, specifically the Free Trade Zones Itabo, San Isidro and Las Americas,
which also enjoy quick access to major seaports and airports.
Medical and pharmaceutical products manufactured by companies in free zones located
in Dominican Republic can be classified into two broad categories: 1) pharmaceuticals and
personal care products, drug compounds, laboratory preparations, disposable products for the
treatment of injury and products hygiene oral and 2) Instruments and appliances used in medical,
surgical and orthopedic, which include a variety of products ranging from devices for transfusion
and treatment of blood components for pacemakers and biopsy needles until prostheses and other
items for orthopedic use.
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Figure 2.7 Distribution of Medical and Pharmaceutical Products Exported by the Dominican
Republic 2013.

Distribution of Value - Exports of Medical and Pharmaceutical
Products - Free Zone- Dominican Republic. Year 2013

26.2%

73.8%

Pharmaceutical Products

Instruments and appliances
used in medical, surgical and
orthopedic

Note. Based on MIT. (2013). Observatory of Economic Complexity-Medical Instruments . Retrieved
December 2014, from MIT: http://atlas.media.mit.edu/profile/hs/9018/

Figure 2.8 Country of Origin of the Medical Manufacturers in the Dominican Republic.

Note. Based on the National Council of Free Zone of the Dominican Republic (CNZF). (2013). Sector Report of
Medical Products and Pharmaceuticals. Dominican Republic. 2013. Retrieved from CNZF:
http://www.cnzfe.gob.do/images/transparencia/Estadisticas/Informes_Tecnicos/Informe-ProductosM%C3%A9dicos-y-Farmac%C3%A9uticos-2013.pdf
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In Figure 2.8, the country of headquarter office of the 26 companies that operates in the
country is distributed by a 85% or 23 companies from United States of America, 7% or 2
companies from the Dominican Republic, 4% or 1 company from Canada, and 4% or 1 company
from Germany.
Figure 2.9 Quantity of Companies by Industrial Park (Medical and Pharmaceutical Sector) in the
Dominican Republic 2013

Note. Based on the National Council of Free Zone of the Dominican Republic (CNZF). (2013). Sector Report of
Medical Products and Pharmaceuticals. Dominican Republic. 2013. Retrieved from CNZF:
http://www.cnzfe.gob.do/images/transparencia/Estadisticas/Informes_Tecnicos/Informe-ProductosM%C3%A9dicos-y-Farmac%C3%A9uticos-2013.pdf

In Figure 2.9, in the Dominican Republic are established 10 industrial parks, where are
located the 26 companies of Medical and Pharmaceutical products.
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Figure 2.10 Percent of Employees Working with Medical Manufacturers by Industrial Park in
the Dominican Republic 2013.

Note. Based on the National Council of Free Zone of the Dominican Republic (CNZF). (2013). Sector
Report of Medical Products and Pharmaceuticals. Dominican Republic. 2013. Retrieved from CNZF:
http://www.cnzfe.gob.do/images/transparencia/Estadisticas/Informes_Tecnicos/Informe-ProductosM%C3%A9dicos-y-Farmac%C3%A9uticos-2013.pdf

In Figure 2.10, we can see the distribution of employees by industrial parks, where
ITABO, Las Americas, and San Isidro represent the major generators of jobs. Due to the level of
technological sophistication of the manufacturing process of these products, these companies
require technical personnel and highly qualified engineering, which receives substantially higher
salaries to those granted in other export activities in the country.
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Figure 2.11 Main Countries of Destination for the Medical Products Manufactured in the
Dominican Republic 2013.

Note. Based on the National Council of Free Zone of the Dominican Republic (CNZF). (2013). Sector Report of
Medical Products and Pharmaceuticals. Dominican Republic. 2013. Retrieved from CNZF:
http://www.cnzfe.gob.do/images/transparencia/Estadisticas/Informes_Tecnicos/Informe-ProductosM%C3%A9dicos-y-Farmac%C3%A9uticos-2013.pdf

In Figure 2.11, we can appreciate the principal countries of destination of exported
products by Sector Medical and Pharmaceutical in the Dominican Republic, where United States
of America receive around 65% of the total production. According to the Trade Competitiveness
Map by UNCTAD, the medical products exported to United States are equivalent to US$675
million, for Canada is US$51 million, Netherlands US$44 million, Japan US$41 million, and
Belgium US$34 million. The country exports around 74 different products to these destinations.
However, behind this relative concentration of exports in the American market, there is a simple
arithmetic logic that could not be ignored in international business; in fact our country has a
unique comparative advantage, located at a relatively short distance from the world's largest
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consumers market. Also, the Dominican Republic has a versatile infrastructure to deliver
operations of supply chain more efficiently in the region with the incorporation of seaports as
Multimodal Caucedo and the application of DR-CAFTA an international free-trade agreement
with the government of United States and other countries from Central America. The DRCAFTA constitutes the first free trade agreement between the US and a small group of
developing countries. It was created with the purpose of creating new and better economic
opportunities by opening markets, eliminating tariffs, and reducing barriers to services. For this
reason, it is necessary to further exploit our geographical potential, promoting the development
of competitiveness of free zones. Recently, the launch of the logistic center of the Zona Franca
Multimodal Caucedo, whose executives have announced a plan to invest US$150 million for the
period 2012-2015, could position our country as an efficient regional center for the
transshipment, consolidation and distribution of goods.
Figure 2.12 Export (US$ Millions) in the Medical and Pharmaceutical Sector. Dominican
Republic 2013.
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Note (Figure2.12). Based on the National Council of Free Zone of the Dominican Republic (CNZF). (2013). Sector
Report of Medical Products and Pharmaceuticals. Dominican Republic. 2013. Retrieved from CNZF:
http://www.cnzfe.gob.do/images/transparencia/Estadisticas/Informes_Tecnicos/Informe-ProductosM%C3%A9dicos-y-Farmac%C3%A9uticos-2013.pdf

In Figure 2.12, the export sales of the sector have grown systematically from 2004
between 10%-12% annually. In 2013, the sector of medical and pharmaceutical products had
exports worth a total of US$ 1,230 million, of which a total of US$322.16 million from
pharmaceutical products, and exports of US$907.84 million of instruments for medical, surgical
and orthopedics, occupying 73.8% of total exports of the sector. Indeed, the sector of surgical
instruments was the most dynamic in the industry, experiencing growth of 14% over 2013, while
exports of pharmaceutical products grew by 8.7% in the same period.
The future success of the scheme of free zones in our country depend to some extent on
the continued diversification into high value-added sectors and incorporating innovative taxes
regime, paying special attention to the promotion of new activities to the synergies with other
national productive sectors. One of the most important aspects of the restructuring of the sector's
exports has been diversifying into higher-technology sectors, which has undoubtedly led to an
increase in value added of the exports. According to a research published by the University of
Oxford, entitled Development Trajectories and New Comparative Advantages: Costa Rica and
the Dominican Republic under Globalization. Free zones in the Dominican Republic have been
even more successful than those located in Costa Rica, in terms of value added exports. This
finding is particularly interesting, since technological escalation of the free zones of Costa Rica,
mainly after installing an Intel manufacturing facility in that country, is frequently cited as a
prominent success story in the region. A good example of the evolution of the value added of
exports from free zones of our country is the relationship between exports and jobs. In 1995,
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exports per employee had a value of US$17.6, while in 2011 its value was US$38.8,
experiencing growth of 121%, significantly higher than the 64% growth of total exports in the
period 1995-2011.
Figure 2.13 Percent of Pharmaceutical Products Exported. Dominican Republic 2013

Note. Based on the National Council of Free Zone of the Dominican Republic (CNZF). (2013). Sector Report of
Medical Products and Pharmaceuticals. Dominican Republic. 2013. Retrieved from CNZF:
http://www.cnzfe.gob.do/images/transparencia/Estadisticas/Informes_Tecnicos/Informe-ProductosM%C3%A9dicos-y-Farmac%C3%A9uticos-2013.pdf

In Figure 2.13, within the category of pharmaceuticals and personal care, one of the
biggest exports was dental floss with a total value up to US$ 34.28 million, where the
multinational company Johnson & Johnson, with over 25 years of operation in the country, took
a leading role. Also, the “dressings packaged for medical use” has decreased in the last three
years from US$72.6 million on 2010 to US$1.47 million or 1% in 2013, this decreased is due to
changes on the supply chain globally of these goods, where China is taking a more significant
role.
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However, after Covidien in 2012 installed a modern manufacturing facility to sterilize
products, this segment “specified sterile products” has experienced an extraordinary shift from
US$0.00 in 2011 to US$141.4 million in 2013.
Figure 2.14 Percent of Medical and Surgical Instruments Exported. Dominican Republic 2013

Note. Based on the National Council of Free Zone of the Dominican Republic (CNZF). (2013). Sector
Report of Medical Products and Pharmaceuticals. Dominican Republic. 2013. Retrieved from CNZF:
http://www.cnzfe.gob.do/images/transparencia/Estadisticas/Informes_Tecnicos/Informe-ProductosM%C3%A9dicos-y-Farmac%C3%A9uticos-2013.pdf

In the figure 2.14, within the category of surgical instruments, the most exported product
was the apparatus for blood transfusion and intravenous, with a total value of US$671 million in
2013, occupying 73% of total exports of medical instruments. Within the group of manufacturers
and exporters of these products highlights US-based multinational Fenwal Blood Technologies,
Hospira, and the German company B. Braun. The Dominican Republic made exports of surgical
instruments with a total value of US$907.84 million in 2013, ranking the 37th position worldwide
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according to International Trade Centre, and standing over countries such as Costa Rica, Turkey,
Portugal, and New Zealand.
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Chapter 3: Methodology
3.1 Methodology
This research project investigated whether R&D expenses have an effect on the profit,
revenue, and productivity for companies of high-tech healthcare products in the Dominican
Republic. This part of the research is constituted by the three main hypotheses that declare:


Companies of high-tech healthcare products in the Dominican Republic, which
invest more in R&D, are more profitable than those who invest less.



Companies of high-tech healthcare products in the Dominican Republic, which
invest more in R&D increases their revenue than those who invest less.



Companies of high-tech healthcare products in the Dominican Republic, which
invest more in R&D increases their productivity levels than those who invest less.

Also, the main research questions are related to: What % of budget is invested in R&D by
manufacturing companies of high-tech healthcare products in the Dominican Republic?; and
What are the barriers to investing resources in R&D in the high tech manufacturers in the
Dominican Republic? In section 3.2 is explained Research Strategy and Data Collection Method.
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3.2 Research Strategy and Data Collection Method


Method
This research adopted a mixed methods approach as both quantitative and qualitative

research methods were used. A quantitative approach was used to measure the level of Research
& Development Expenditure for companies of high-tech healthcare products in the Dominican
Republic. In quantitative research, the goal is to determine the relationship between one thing (an
independent variable) and another (a dependent or outcome variable) in a population (USC
Libraries, 2014). In this sense, the quantitative approach allowed us to determine correlation
between the variables stated in the hypotheses of this research, where the dependent variables are
(profits; revenue; and productivity) and the independent variable is (R&D expenditure) for this
study. Also, the quantitative research helped us to analyze empirical result from the survey for a
reliable conclusion of the level of Research & Development for companies of high-tech
healthcare products in the Dominican Republic.
With the quantitative data provided by the survey developed for this research (see
Appendix A for the survey questions), we were able to determine these metrics: Expenditure on
in-house R&D; the source of funds for in-house R&D expenditure; the numbers of employees
working in R&D; the type of employees working in R&D (researchers, technicians, staffs);
whether R&D is performed in-house or outsourced; and the number of patents registered. The
information gathered from these metrics allowed us to answer the first research questions: What
% of budget is invested in R&D by manufacturing companies of high-tech healthcare products in
the Dominican Republic? The result was calculated with the help of Microsoft Excel.
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In this context, it was necessary also to perform some content analysis together with the
quantitative research to answer the three hypotheses of this research. The content analysis was
used to complete information related to: global R&D expenditure performed by the companies
surveyed, US$ sales globally performed by the companies surveyed, and US$ profits globally
performed by the companies surveyed. These metrics were gathered from the annual reports
provided by the companies surveyed via e-mail or through their web page. Content analysis was
used because many of these companies consider their international manufacturing facilities as a
dependent unit from their headquarters. For that reason, to develop a more reliable study it was
necessary to use the data gathered from the annual reports of the surveyed companies. The three
hypotheses were answered by the information provided from the quantitative research of the
survey and the data gathered from the annual reports of the companies surveyed.
The hypotheses were answered using statistical functions of Microsoft Excel as
correlations, average, and ratio. The correlation test was used to measure the strength of a linear
association between two variables, where the value r = 1 means a perfect positive correlation and
the value r = -1 means a perfect negative correlation with the objective to prove the relationship
between R&D expenditures with profits and R&D expenditures with revenue. For the first
hypothesis, “Companies of high-tech healthcare products in the Dominican Republic, which
invest more in R&D, are more profitable than those who invest less”, after we gathered the data
history of the last 4 years from the annual reports such as Global R&D Expenditure, Global
Revenue, and Global Profit; we calculated the coefficient correlation of the variables (R&D
Global Expenditure with Global Profit) for each company. After completing the coefficient of
correlation for each surveyed company, we calculated an overall average that represents the final
result to answer the first hypothesis.
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The second hypothesis, “Companies of high-tech healthcare products in the Dominican
Republic, which invest more in R&D increases their revenue than those who invest less”. We
calculated the coefficient correlation of the variables (R&D Global Expenditure with Global
Revenue). To answer this hypothesis the process was the same as that used for the first
hypothesis only that the dependent variable was (Revenue).
For the third hypothesis, “Companies of high-tech healthcare products in the Dominican
Republic, which invest more in R&D increases their productivity levels than those who invest
less” it was necessary to perform another analysis to measure the productivity based on R&D
expenditures. Known as return on research capital, or RORC, the metric effectively measure the
proportion of profits that are generated from R&D spending in a previous period. RORC tells us
how much gross profit is generated for every dollar of R&D spent in the previous year. For this
analysis, we used the ratio (Current Year Gross Profit) / (Previous Year R&D Expenditure).
In addition to the quantitative research described above, it was also necessary to perform
some qualitative research in order to answer the second research question. Two telephone
interviews with general managers in 2 high-tech healthcare companies in the Dominican
Republic were conducted in order to develop a better understanding of the issues related to R&D
that affect the competitiveness and innovation of our industries. Some questions were:
1. What factors do you consider in making decisions about R&D? What influences the
decision making process?
2. What are the barriers to investing more resources in R&D in the Dominican Republic?
3. What kinds of R&D does your company conduct or has conducted?
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 Data Collection
There are two sources of data for research, namely primary and secondary data. The
primary data is relevant to the present study and usually collected by the researcher through
communication methods or interaction with respondents and observation methods. For this
study, survey techniques were used to answer the research questions and test the hypotheses.
Secondary data was gathered from previous studies through various sources such as articles,
information posted on the internet, organizational databases, and government surveys.



Sample Selection
According to the Ministry of Economy, Planning and Development of the Dominican

Republic and the National Free Zones Council, in the last census of 2013, 26 companies that
manufacture high-tech healthcare products operate in the country. As a result, using a sample
size calculator from Raosoft1, the recommended statistically sample size for the project was 25
with a 5% of margin error, confidence level of 95%, response distribution of 50%, and
population size of 26. In this context, letters and e-mails were sent to the 26 companies (general
managers) that represent the Medical and Pharmaceutical Industry of the Dominican Republic,
explaining the research purpose and offering the opportunity to participate in the survey. A total
of 10 companies rejected participation. This represents a response rate of 62%. The remaining 16
companies formed the basis of the sample for the study. These companies received a
questionnaire online or a telephone interview requesting quantitative responses. The companies
surveyed for this project were: B. Braun AG, Baxter, CareFusion, Covidien, Edward Lifescience,
Fresenius-Fenwall, Hospira, Johnson & Johnson Dental Care, ConvaTec, Ecolab-Microtek, De

1

http://www.raosoft.com/samplesize.html
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Royal, Accu-Med Technologies, Arriol International, Oscor Caribe, CEA Global Dominicana,
and Medsorb. The two interviews requested for this study were selected randomly, where Felipe
Sandoval

(General

Manager-B.Braun

Dominicana)

and

Miriam

Aybar

(General

Manager/Fresenius-Fenwall Dominicana) were selected. The data collected directly from the
companies represents the primary data of the present study.
Additional, secondary data required for this study was obtained from the Annual Reports
of: B. Braun AG, Baxter, CareFusion, Covidien, Edward Lifescience, Fresenius-Fenwall,
Hospira, Johnson & Johnson Dental Care, Ecolab-Microtek, and ConvaTec. Other secondary
data were provided by studies from: Innovation and Global Competitiveness Index 2015 by The
World Economic Forum; Global Innovation 1000: Why Culture is Key 2011 by Booz &
Company; Why “Low Risk” innovation is Costly 2011 by Accenture; and Foreign Direct
Investment, The Transfer And Diffusion Of Technology, And Sustainable Development, 2011
provided by the United Nations Conference on Trade and Development.
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Chapter 4: Results
4.1 Collected Data
What follows is a synthesis of the data collected in this study.

Figure 4.1 Country of Origin of the Medical Manufacturers in the Dominican Republic (Survey)

2

1

13

United States of America

Dominican Republic

Germany

Source: by the authors

In Figure 4.1, the results of the companies surveyed show that 81.25% or 13 companies
have their Headquarter Office in the United States of America, 12.5% or 2 companies in the
Dominican Republic, and 6.25% or 1 company in Germany.
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Figure 4.2 Percent of Manufacturers of Medical Instruments with a R&D unit in the Dominican
Republic.

Source: by the authors

In Figure 4.2, from the 16 companies surveyed 62% or 10 companies have a technical
facility for R&D activities, and 38% or 6 companies don’t have R&D facilities in the Dominican
Republic. However, is necessary to consider that the statistics of this chart don’t represent a
complete or fully operative R&D unit during the whole year in the companies surveyed, due to
many of the R&D activities are related to specific project required for a particular population,
improvement of products and processes, and any customer specification. In this context, the
manufacturing facility of the companies surveyed in this study, such as (Covidien, B. Braun AG,
Baxter, Fresenius-Fenwall and Edward Lifescience) are supporting specific global process of
research, design, development, and manufacturing of new or the improvement of existing
products depending on the guidelines of the headquarter office.

MEASURING AND PROMOTING R&D IN THE DOMINICAN REPUBLIC

35

Figure 4.3 Percent of Intensive R&D process performed by the Head Office.

Source: by the authors

In Figure 4.3, we can see that 87% or 14 companies perform their R&D process outside
the country. The R&D process is developed globally using Innovation Centers to encourage a
more flexible and dynamic innovation process. 13% or 2 companies are “manufacturer
contractors”; they don't need to perform any R&D process, as patents, designs, and standards are
supplied by the developer.
Figure 4.4 Percent of R&D is performed in-house or outsourced.

Source: by the authors
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In Figure 4.4, the result is similar to Figure 4.3, but the principal characteristic is the
predominance to perform any R&D process “in-house”.
Figure 4.5 Did your company (Manufacturer of Medical Instrument) engage in joint R&D
projects with any of the following?

Source: by the authors

In Figure 4.5, as we can see that no companies in the medical and pharmaceutical sector
work with universities or specialized firms in the Dominican Republic to perform any R&D
process. Also, from the surveyed companies only 14 companies have worked with specialized
firms outside of the Dominican Republic to perform any R&D process and 5 companies are
engaged with specific research programs from international recognized universities outside of
the Dominican Republic.
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Table 4.1 Overall variables of the companies surveyed.
Companies

B. Braun AG

Baxter

CareFusion

Covidien

Edward Lifescience

Fresenius

Hospira

Johnson & Johnson

ConvaTec

Ecolab-Microtek

Years
2010
2011
2012
2013
2011
2012
2013
2014
2011
2012
2013
2014
2011
2012
2013
2014
2011
2012
2013
2014
2011
2012
2013
2014
2011
2012
2013
2014
2010
2011
2012
2013
2010
2011
2012
2013
2011
2012
2013

Source: by the authors

Expenditure R&D
Global (US$
Million)
$
196.37
$
226.66
$
241.55
$
275.87
$
915.00
$
946.00
$
1,156.00
$
1,246.00
$
146.00
$
164.00
$
192.00
$
190.00
$
447.00
$
412.00
$
479.00
$
508.00
$
204.40
$
246.30
$
291.30
$
323.00
$
96.53
$
110.83
$
111.63
$
125.81
$
300.50
$
258.80
$
303.60
$
301.70
$
6,844.00
$
7,548.00
$
7,665.00
$
8,183.00
$
52.60
$
45.40
$
39.90
$
32.00
$
96.00
$
183.00
$
188.00

Revenue (US$
Million)
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$

5,581.57
5,817.06
6,370.32
6,523.91
12,843.00
13,893.00
14,190.00
15,259.00
3,440.00
3,598.00
3,550.00
3,842.00
10,429.00
9,607.00
9,851.00
10,235.00
1,447.00
1,678.60
1,899.60
2,045.50
11,844.19
12,570.52
13,800.28
14,609.73
3,917.20
4,057.10
4,092.10
4,002.80
61,600.00
65,030.00
67,224.00
71,312.00
1,513.10
1,598.60
1,646.20
1,700.70
6,799.00
11,839.00
13,253.00

Profit (US$
Ratio R&D/Revenue
Million)
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$

350.08
325.22
364.21
398.16
1,420.00
2,224.00
2,326.00
2,012.00
249.00
293.00
385.00
417.00
1,632.00
1,868.00
1,905.00
1,700.00
218.00
236.70
293.20
391.70
978.52
1,071.15
1,186.81
1,109.89
357.20
(9.40)
44.20
(8.30)
13,334.00
9,672.00
10,853.00
13,831.00
(609.90)
(285.30)
(161.10)
(173.10)
462.50
703.60
967.80

4%
4%
4%
4%
7%
7%
8%
8%
4%
5%
5%
5%
4%
4%
5%
5%
14%
15%
15%
16%
1%
1%
1%
1%
8%
6%
7%
8%
11%
12%
11%
11%
3%
3%
2%
2%
1%
2%
1%

Average
R&D/Revenue
Global

Expenditure R&D
Local

4%

0.02%

8%

0.01%

5%

0.00%

5%

0.05%

15%

0.01%

1%

0.01%

7%

0.01%

11%

0.00%

3%

0.00%

1%

0.00%
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Figure 4.6 Global Average R&D Expenditure vs. Local Expenditure on R&D.
Global Average R&D Expenditure Vs. Local Expenditure on R&D
16%
14%
12%
10%
8%
6% 4%
4%
2% 0.02%
0%

15%
11%
8%

7%
5%

5%
3%

0.01%

0.00%

0.05%

0.01%

Average R&D/Revenue Global

1%
0.01%

0.01%

0.01%

0.00%

1%
0.00%

Expenditure R&D Local

Source: by the authors

Of the 16 companies surveyed only 10 agreed to provide an overall statistic about their
R&D activities. This information is presented in Figure 4.6 and Table 4.1. As mentioned, these
companies concentrated many of its R&D abroad. Figure 4.6 shows the Global Average R&D
Expenditure vs. Local Expenditure in R&D by these companies from 2009 to 2014, according to
the calculated ratio (R&D/Revenue) globally from each one; the highest percentage is invested
by Edward Lifescience 15%, followed by Johnson & Johnson with 11%, Hospira with 7%, and
Baxter with 8%. These percentages represent a strong commitment for these companies to invest
on R&D activities. However, is necessary to consider that local expenditure in R&D activities is
so low comparable to international expenditure. The Figure 4.6 indicates us that the overall
expenditure in the Dominican Republic for the Sector Medical and Pharmaceutical is around
0.01% annually.
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Figure 4.7 Sources of Funds for R&D in the Dominican Republic.

Source: by the authors

In Figure 4.7, the principal source of funding for new R&D activity in the Dominican
Republic is provided by the own company. So far, none of the companies surveyed have
received subsidies from Dominican institutions or from the government of the Dominican
Republic to perform any R&D activity.
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Figure 4.8 Areas of Expenditure in R&D by the companies surveyed.

Source: by the authors

As can be seen in the Figure 4.8, the principal areas of expenditure on R&D globally by
the firms surveyed are: in the areas of applied research and experimental development. In this
context, Covidien in the Dominican Republic is the only one that has 5 employees (engineers
with Ph.D. and master’s degree) in its plant of San Isidro working specifically on special projects
in R&D assigned by the Headquarter office. The other 13 companies surveyed in the country
only perform process innovation and product testing, which are performed by the General
Manager or engineer managers in areas such as quality, process or products. None of the
surveyed company registered a patent in the Dominican Republic in the last two years. Also, in
the Dominican Republic there is no up-to-date information on the number of patents requested
and granted, although available information seems to indicate little interest or capacity to patent
and a high foreign participation in patent applications.
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Interviews

 Interview with Felipe Sandoval (General Manager B. Braun Dominican Republic)

1) What factors do you consider in making decisions about R&D? What influences
the decision making process?
In our experience, we find that complexity in its many forms slows innovation. That is
the reason why we encourage our organization to find innovative way to improve our
process and suggest new ideas for products. Every company in this sector has a product
development plan with major milestones and activities in place. For B. Braun
innovation is our DNA, each year the company globally rewards creative ideas with the
Innovation Prize. The brand value of “Innovation” in B.Braun also finds its expression
in state-of-the-art production facilities; we will be investing US$2.9 billion worldwide
between 2011 and 2015 in manufacturing facilities for all product areas, the largest
investment program in our history. In general, our roadmap related to decision making
about R&D we have: understand the customer ecosystem and prioritize customer needs,
optimize project team resources, and align R&D processes to deliver cost-effective and
differentiated products to the market.

2) What are the barriers to investing more resources in R&D in the Dominican
Republic?
In perspective, is necessary to consider that innovation process in the Sector Medical
and Pharmaceutical in the Dominican Republic is driven by building state-of-the-art
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production facilities more than developing the product in the country. In general, the
difficulty to install a sterilization facility for all the products manufactured in the
Dominican Republic is related to the high costs of installation. If companies could
sterilize and distribute directly into the local market, companies would save between 10
to 12 days in the process. Some other barriers are: low level of public investment in
R&D; limited absorption and use of technologies by the public and private sectors.

3) What kinds of R&D does your company conduct or has conducted?
We have a R&D technical facility that is supporting the process of design and
development of new products globally. This includes: perform process innovation and
test of product that are related with applied research.
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 Interview with Miriam Aybar (Fresenius-Fenwall Dominicana)

1) What factors do you consider in making decisions about R&D? What influences
the decision making process?
The principal focus of all our activities is to improve the quality of life for our patients
by making advances in therapy and technology. Innovations from research and
development are the key. Our commitment to research and development places the very
best equipment at patients' disposable today and helps to shape the standards of
tomorrow. Before starting any product development we ask: What can we do better?

2) What are the barriers to investing more resources in R&D in the Dominican
Republic?
Inadequate policies and legal framework for promoting alliances between industry and
universities for the protection of R&D activities and for attracting advanced
technologies and investors.

3) What kinds of R&D does your company conduct or has conducted?
In 2013, 552 full-time employees were working in R&D worldwide. Most activities are
carried out at the German sites Schweinfurt and Bad Homburg. Other R&D sites are in
St. Wendel (Germany), Bucharest (Romania) and Krems (Austria). The global R&D
organization coordinates cooperation and technology exchange between the various
sites.
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Hypothesis Testing

Table 4.2 Correlation Coefficient Test
Correlation Coefficient
Variable

Correlation

R&D Global Expenditure -Revenue

0.9793

R&D Global Expenditure -Profits

0.9759

Source: by the authors

In this perspective, the analysis on Microsoft Excel of the correlation of the variables
(R&D Global Expenditure-Revenue and R&D Global Expenditure-Profits) indicated us that
variables are highly and positively correlated, this means that a change or improvement in one of
the variable (R&D expenditure) has strong and direct effect on the other variables (Revenues and
Profits). Also, we have evaluated the expenditures assigned for R&D activities for these
companies in the Dominican Republic, but the average are so low to perform a significant
analysis. For that reason, the analysis had to be performed by using the public Annual Reports
from 2009-2014 of these companies. As we have explained, the manufacturing facilities that
operate these companies in the Dominican Republic need to be considered as part of the global
Research process and value chain of the companies.
Therefore, by using the global R&D expenditure made by each enterprise, we improved
significantly the relevance of the data. This first analysis confirmed us our first hypothesis
“Companies of high-tech healthcare products in the Dominican Republic, which invest more in
R&D, are more profitable than those who invest less”. The coefficient of correlation for (R&D
Global Expenditure –Profits) is 0.9759; this means that variables are highly and positively
correlated for the data collected.
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The second hypothesis “Companies of high-tech healthcare products in the Dominican
Republic, which invest more in R&D increases their revenue than those who invest less” is
evaluated according to the global revenue by each company surveyed. The coefficient of
correlation (R&D Global Expenditure –Revenue) for this hypothesis is 0.9793; this means that
variables are highly and positively correlated for the data collected. For that reason, we
confirmed our second hypothesis. However, R&D spending by itself does not guarantee
profitability and strong stock performance; it’s more about an extraordinary commitment to
develop the right innovation culture, strategic alignment, and efficient processes inside the
company that allow to exploit the potential of R&D expenditure effectively. According to the
report (Global Innovation 1000: Why Culture is Key, 2011) by Booz & Company, companies
should follow the lead of the most successful innovators in ensuring that the company’s culture
not only supports innovation, but actually accelerates its execution. They suggest first, make sure
that the innovation strategy is clearly articulated, and communicated throughout the organization
from the top all the way down to the lab bench. Second, align the technical community with top
management, and give the technical leaders a real seat at the executive table. Third, ensure that
the innovation agenda translates into a tangible action plan, clearly linked to a short, focused list
of capabilities that will allow the company to stand out in the marketplace.

For the third hypothesis “Companies of high-tech healthcare products in the Dominican
Republic, which invest more in R&D increases their productivity levels than those who invest
less” was necessary to perform another analysis to measure the productivity based on R&D
expenditures. Known as return on research capital, or RORC, the metric effectively measure the
proportion of profits that are generated from R&D spending in a previous period. At the same
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time, it gives investors a sense of whether recent R&D investments are contributing to financial
performance or whether the company is just coasting on older innovations (Investopedia, 2013).
RORC tells us how much gross profit is generated for every dollar of R&D spent in the previous
year.
The ratio is expressed as:

Table 4.3 RORC (return on research capital) for B.Braun Ag and Covidien.
Companies

Year

B. Braun AG
Covidien

Expenditure R&D
Global (US$ Million)

2013 $
2014 $

Revenue (US$
Million)

275.87 $
508.00 $

6,523.91 $
10,235.00 $

Gross Profit

2,958.76 $
6,085.00 $

Profit (US$
Million)

RORC R&D

398.16 $
1,700.00 $

Source: by the authors

As we can see in the table 4.3, the companies B. Braun AG and Covidien were
considered for this analysis because they are deploying some R&D activities in the country. For
that reason, RORC ratio indicated us that B. Braun AG produced US$12.25 of gross profit in
2013 for every dollar that it spent on R&D globally and Covidien produced US$12.70 of gross
profit in 2014 for every dollar that it spent on R&D globally. With this consideration, the
expenditures for R&D made by these companies increased the productivity level overall and we
have confirmed our third hypothesis.

12.25
12.70
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Chapter 5: Conclusion and Recommendations
5.1 Discussion and Conclusion
As globalization intensifies, many multinational companies have internationalized their
R&D activities; and new opportunities have been opened up for developing countries to attract
R&D-intensive foreign direct investment (FDI). R&D is recognized as an important driver of
economic and social progress worldwide. In this context, investing more in R&D is a way to
improve innovation and economic growth, in order to increase the competitiveness of the
Dominican Republic in the global market. Investing in R&D has great potential for benefiting
broader society. This research project investigated whether R&D expenses have an effect on the
profit, revenue, and productivity for companies of high-tech healthcare products in the
Dominican Republic, and why some of these companies do not invest more in R&D.
The survey developed for this investigation project was answered by 16 of the 26
Medical and Pharmaceutical manufacturers in the Dominican Republic. This represented a
response rate of 62%. Of the 16 companies that answered the survey, 10 companies have a
technical facility for the global R&D process, and 6 companies don’t have any kind of R&D or
technical facilities for innovation process in the Dominican Republic. In this context, it’s
important to note that none of these companies have performed a significant R&D process in the
country in the last 5 years. From this perspective, the facilities that these companies have in the
country serve manufacturing process and supply chain capabilities. At the same time, some
companies have been incorporated continuously new products and production processes with
more complexity, including the adoption of vertical integration strategies for manufacturing

MEASURING AND PROMOTING R&D IN THE DOMINICAN REPUBLIC

48

production materials and intermediate components, which has impacted positively on increasing
the value added of exports.
For example, within the category of medical instruments, the most exported product was
the apparatus for blood transfusion and intravenous, with a total value of US$671 million in
2013, occupying 73% of total exports of medical instruments. Within the group of manufacturers
and exporters of these products highlights US-based multinational Fenwal Blood Technologies,
Hospira, and the German company B. Braun.
The Dominican Republic made exports of medical instruments with a total value of
US$952.03 million in 2013, ranking the 18th position worldwide according to the Observatory of
Economic Complexity developed by the MIT (Massachusetts Institute of Technology), where the
Dominican Republic is standing over countries such as Austria and Malaysia. At the same time,
this makes the country the second largest Latin American exporter of these products. In this
context, none of these companies sell their products in the local market; the reasons behind this
decision are that each product need to pass a sterilization process and complete the assemble
process in the most cases in United States, China or Canada. In general, the difficulty to install a
sterilization facility for all the products manufactured in the Dominican Republic is related to the
high costs of installation. According to CEO -B. Braun Dominican Republic-Felipe Sandoval, if
companies could sterilize and distribute directly into the local market, companies would save
between 10 to 12 days in the process. Although, Covidien was the first to install a sterilization
plant in 2011 for specific products, however the final process of the product is terminated in the
United States.
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In the question “Did your company engage in joint R&D projects with any of the
following?” of the survey, we saw that no companies in the medical and pharmaceutical sector
work with universities or specialized firms in the Dominican Republic to perform any R&D
process. In some cases, R&D is also considered the least internationalized segments of the value
chain. According to the report (Foreign Direct Investment, The Transfer And Diffusion Of
Technology, And Sustainable Development, 2011) provided by the United Nations Conference
on Trade and Development, transnational corporations have been increasingly shifting their
R&D activities to the developing world, though developed countries remain the main host
locations of foreign R&D activities by transnational corporations. For example, the United States
did not use much developing country affiliates in their foreign R&D activities, but they allocated
globally 15% of their R&D activities in 2007. The foreign direct investment in R&D can bring
various benefits to host countries. While the empirical evidence is limited, what exists suggests
that when supported and complemented by proactive policies, such benefits as: promoting
human resource development, creating knowledge spillovers, and upgrading industrial
competitiveness – may have significant potential for technological learning in developing
countries (UNCTAD, 2005).
However, according to the same report (Foreign Direct Investment, the Transfer and
Diffusion of Technology, and Sustainable Development, 2011) provided by the United Nations
Conference on Trade and Development, in many case transnational corporations do not have an
interest in transferring knowledge to and supporting innovation in foreign affiliates beyond what
is needed for their production process or product.
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The government support to facilitate the acquisition or use of such technology and
process of learning foreign technology is critical. Part of the success of transfer of technology at
the firm level depends on the existence of the support from domestic institutes in adapting to new
situations faced by local firms.
As we have analyzed, the companies surveyed concentrate their R&D programs outside
the country because in this moment the Dominican Republic don’t have the quality or the
capacity through government or academic institutes to engage in complex R&D activities
required by these firms. In the table 4.1 presented in this study about the Global Average R&D
Expenditure vs. Local Expenditure in R&D by these companies from 2009 to 2014, according to
the calculated ratio (R&D/Revenue) globally from each one; the highest percentage is invested
by Edward Lifescience 15%, followed by Johnson & Johnson with 11%, Hospira with 7%, and
Baxter with 8%. These percentages represent a strong commitment for these companies to invest
on R&D activities, for example the biggest investor on R&D activities is Johnson & Johnson
with US$8,183 million in 2013.
However, is necessary to consider that local expenditure in R&D activities in the
Dominican Republic is so low compared to international expenditure. To answer our first
research question the data analyzed indicates us that the overall expenditure in the Dominican
Republic for the Sector Medical and Pharmaceutical is around 0.01% annually, where B. Braun
and Covidien are increasing their efforts to implement effective R&D activities in the country,
although this percentage is minimum, both companies have exports for above US$100 million
annually in the country.
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Also, the companies surveyed in the country only perform process innovation and
product testing, which are performed by the General Manager or engineer managers in areas
such as quality, process or products. None of the surveyed company registered a patent in the
Dominican Republic in the last two years. According to the (World Competitiveness Report,
2015) developed by the World Economic Forum, the Dominican Republic ranks on the position
80th from 144 countries worldwide on patents applications/million population or 0.5 patent
application/population million (see Table 5.1). The data provided by the World Economic Forum
also shows that the pillar of innovation in the Dominican Republic is composed by capacity of
innovation (53%), quality of scientific research institutions (41%), company spending on R&D
(40%), university-industry collaboration in R&D (47%), and availability of Scientifics and
engineers (40%).
Table 5.1 Innovation Index by the World Economic Forum-Dominican Republic 2015

Note. From the World Economic Forum. (2014). The Global Competitiveness Report 2014-2015.
Retrieved from World Economic Forum: www.weforum.org/issues/global-competitiveness
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Figure 5.1 Insights on Innovation

Note. From Accenture. (2013). Why “Low Risk” innovation is Costly. Retrieved October 2014,
from

Accenture:

http://www.accenture.com/sitecollectiondocuments/pdf/accenture-why-low-risk-

innovation-costly.pdf

However, it’s important to note the evaluation in the report Why “Low Risk” innovation
is Costly from Accenture; about the potential of innovation based on R&D activities, as we can
appreciate in Figure 5.1, companies have committed in 51% to investing resources and
organizational capacity to drive innovation also in time of market volatility. Thus, companies are
willing to implement new managerial responses to facilitate innovation with the creation of the
Chief Innovation Executive (CIE); in 2012 there were 60% of global companies with CIE.
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In general, during this research we have found that the barriers to investing more
resources in R&D in the high tech manufacturers sector in the Dominican Republic were:

o Low level of public and private investment in R&D;
o Limited absorption and use of technologies by the public and private sectors;
o Fragmented sources of human resources and limited access to cutting-edge
knowledge;
o Unclear priorities for scientific and technological development in this sector;
o Inadequate policies and legal framework for promoting alliances between
industry and universities for the protection of R&D activities and for
attracting advanced technologies and investors;
o Limited interaction among industry, the universities and the Government;
o Limited channels for interaction between institutions for the development of
knowledge and technology;
Today, the Dominican Republic is a hub for top medical technology companies which
have chosen the country for manufacturing a wide range of sophisticated medical products,
creating one of the largest clusters in healthcare manufacturing in the region. In this sense, the
medical device industry in the Dominican Republic has played a key role in promoting and
sustaining economic growth of the country, due to a significant and sophisticated network of
experienced people and companies, whom are incorporating new and advanced manufacturing
process. However, in the case of the transfer of technology from the universities to industry, it is
necessary to develop the best strategies and policies that allow the universities and all researchers
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involved in the R&D process, to pursue a future commercialization of their inventions or
innovations.
This insight is a way to understand the actual situation of R&D in the Dominican
Republic with the purpose for developing new strategies to foster new R&D program in the
country. The data collected was used to gain a better perspective of the reality of R&D process in
one of the most profitable industries (Medical and Pharmaceutical Industry). With this improved
perspective, the information collected in this study will be submitted to government institutions,
such as: PROINDUSTRIA (Center for Industrial Development and Competitiveness),
ADOZONA (Dominican Association of Free Zones), and CONEP (National Council of Private
Enterprise) as a contribution to the national policy in competitiveness. Also, the study could be
used to open a debate forum in PUCMM about the possibilities to enhance the relationships
between R&D, industries, and universities in the Dominican Republic.
As we have seen, the purpose of this research was to try to understand whether R&D
expenses have an effect on the profit, revenue, and productivity for companies of high-tech
healthcare products in the Dominican Republic, and why some of these companies do not invest
more in R&D. The results of this research are conclusive in this matter, the analysis on Microsoft
Excel of the correlation of the variables (R&D Global Expenditure-Revenue and R&D Global
Expenditure-Profits) indicated us that variables are highly and positively correlated, this means
that a change or improvement in one of the variable (R&D expenditure) has strong and direct
effect on the other variables, in this case with Revenues or Profits. However, R&D spending by
itself does not guarantee profitability and strong stock performance; it’s more about an
extraordinary commitment to develop the right innovation culture, strategic alignment, and
efficient processes inside the company that allow to exploit the potential of R&D expenditure
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effectively. This study has showed also that cooperation in the Dominican Republic among
(company-university-government) in the innovation system is ineffective. The companies
surveyed concentrate their R&D programs outside the country because in this moment the
Dominican Republic don’t have the quality or the capacity through government or academic
institutes to engage in complex R&D activities required by these firms. The overall expenditure
in R&D in the Dominican Republic for the Sector Medical and Pharmaceutical is around 0.01%
annually. In many developing and transition economies, international companies generally
perform little R&D and don’t promote new partnership inside the country. In this context,
government policies need to encourage both domestic and foreign investments in building
productive and adaptive capacities, fostering business linkages, enhancing spillover effects, and
promoting technological advances. In this sense, when stakeholders of R&D and innovation
activities share common values and trust, scientific and technological outcome tends to be
maximized, leading to enhanced competitiveness. The internationalization of R&D by
transnational corporations opens up new opportunities for developing countries as the Dominican
Republic to enhance the development of its own innovative capabilities.
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5.2 Recommendations


Institutionalize R&D statistics. Unfortunately, the current R&D statistics database in
the Dominican Republic is outdated and this represents an important issue for policy
planning to foster the national competitiveness. In this sense, is necessary to establish a
sustainable R&D statistical system that contemplates better ways to measure innovation,
R&D activity, and intangible capital. As a nation will be more effective to us promote
innovative activity if we are able to measure its role in economic growth and social
wellness.



Encourage public capacity in R&D by investing in local universities and research
institutes. A key challenge for developing countries is to strengthen their universities and
public research institutes by recruiting adequate staff and providing them with adequate
funding and equipment to carry out R&D and by providing postgraduate education in
science and technology subjects, as demanded by foreign investors in R&D.



Create a Collaborative Research and Development Platform using Social Media. A
collaborative research and development social platform could bring together businesses
and academic partners for projects that can lead to successful new products, processes
and services.
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Redesign Law 392-07 about Competitiveness and Innovation. Enhance the capacity of
the Law to promote Foreign Direct Investment (FDI) in areas of Research and
Development that includes:


Develop a better intellectual property rights regime. The main drawback of
R&D off shoring is the risk of intellectual property theft. Therefore, another
priority for governments aiming to attract R&D through FDI (Foreign Direct
Investment) is to develop a clear and enforceable intellectual regime.



Fiscal incentives to business. Fiscal incentives can include a favorable tax
treatment for R&D expenditure, for example in the form of accelerated
depreciation or import tariff exemptions.



Creating clusters for fostering linkages. The establishment of science and
technology parks that can be used to create a more conducive environment for
innovation and R&D in companies across the country, often in close proximity
to universities and other public research institutions. Building a dynamic
national innovation system where universities and public research institutes
collaborate with firms is critical to attract R&D through FDI and to capture the
associated knowledge spillovers.



Universities develop programs related to reverse Engineering. The objectives of
reverse engineering are usually to understand the structure and functioning of an object in
order to make a new device or program. In this sense, a similar object is created in a
different way by improving on it, where minor or incremental changes are the most
frequent type of innovation activity in emerging economies and developing countries.
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Appendix A: Survey Research and Development Activities

1. Does your company have a dedicated R&D unit/department?: Yes____ No____
2. Is the R&D process performed by the Head Office? Yes____ No____
3. R&D is performed in-house or outsourced: Yes____ No___
4. Did your company engage in joint R&D projects with any of the following?
Joint R&D Projects with:
Please indicate
(Yes/No)
Other firms in the Dominican Republic
Other firms outside of the Dominican
Republic
Universities in the Dominican Republic
Universities outside of the Dominican
Republic
5. Expenditure on R&D (US$) at least in the last five years:
Years
R&D Expenditure (US$)
% R&D in the budget

6. The source of funds for R&D expenditure:
Source of Funds

Please Indicate (Yes/No):

Company’s own sources
Direct grants from national, federal state,
provincial and local government
Government research institutes
7. Please indicate R&D expenditure in terms of the following categories:
Categories:
Please Indicate (Yes/No):
Basic Research
Applied Research
Experimental Development
8. The numbers of employees working on R&D in the Dominican Republic:_________

64

MEASURING AND PROMOTING R&D IN THE DOMINICAN REPUBLIC
9. Type of employees working on R&D (researchers, technicians, staffs)
Employed as:
Total
PhD qualified researcher
Other researcher
Technicians
Support Staffs
Total R&D staff
10. Number of patents developed with R&D program in the Dominican Republic
:___________
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